What laboratory markers are recommended for evaluating familial hypercholesterolemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Laboratory Markers for Familial Hypercholesterolemia

The essential laboratory markers for evaluating familial hypercholesterolemia are LDL-cholesterol measured on at least two occasions (ideally fasting), followed by genetic testing for pathogenic variants in LDLR, APOB, PCSK9, and LDLRAP1 genes. 1

Primary Laboratory Evaluation

LDL-Cholesterol Measurement

LDL-cholesterol is the cornerstone laboratory marker and should be measured with specific attention to:

  • Measure on at least two separate occasions (>2 weeks but <3 months apart) to confirm elevation 1
  • Ideally obtain fasting samples, though non-fasting samples may be considered for initial screening 1
  • Use caution with the Friedewald equation when triglycerides are elevated, as hypertriglyceridemia confounds LDL-C estimation 1

Age-Specific LDL-C Thresholds:

Adults:

  • LDL-C >4.9 mmol/L (≥190 mg/dL) triggers opportunistic screening 1
  • Use age-specific, sex-specific, and country-specific values above the 95th percentile for population screening 1

Children and Adolescents:

  • LDL-C >4.9 mmol/L (>190 mg/dL) on two occasions = highly probable FH (with parental history) 1
  • LDL-C >4.0 mmol/L (>160 mg/dL) = probable FH with parental history of high LDL-C or premature ASCVD 1
  • LDL-C >3.5 mmol/L (>135 mg/dL) = probable FH when parent has confirmed pathogenic variant 1

Homozygous FH:

  • LDL-C >10 mmol/L (>400 mg/dL) on two occasions, especially with physical stigmata before age 10 1

Critical Measurement Considerations:

  • If patient is on lipid-lowering therapy, adjust LDL-C for medication effect (statins, ezetimibe, PCSK9 inhibitors) when no pretreatment value is available 1
  • With severe hypertriglyceridemia >4.5 mmol/L (>400 mg/dL), re-screen with 12-hour fasting sample and use direct LDL-C assay 1
  • Exclude secondary causes of elevated LDL-C before making the diagnosis 1

Genetic Testing (Gold Standard)

Genetic testing should be performed whenever possible as it provides definitive diagnosis and enables cascade screening of family members 1. This is particularly critical when phenotypic features are less obvious, such as in children.

Genes to Test:

The pathogenic variants that impair the LDL-receptor pathway include:

  • LDLR (LDL receptor gene) - most common
  • APOB (Apolipoprotein B-100 gene)
  • PCSK9 (Proprotein convertase subtilisin/kexin type 9 gene)
  • LDLRAP1 (LDL receptor adaptor protein 1) - rare
  • APOE - rare 2

Important caveat: If the phenotype strongly suggests FH but genetic testing is negative, do not exclude FH - approximately 25-75% of clinically diagnosed cases have no identifiable causative variant 2. This may represent polygenic hypercholesterolemia.

Supplementary Laboratory Markers

Cholesterol Metabolism Markers (Research Context)

While not routinely used clinically, noncholesterol sterols can help differentiate FH subtypes 3:

  • Cholesterol synthesis markers: desmosterol and lanosterol
  • Cholesterol absorption markers: sitosterol and campesterol

These markers may distinguish familial combined hyperlipidemia (FCHL) from other genetic hypercholesterolemias, as FCHL shows increased cholesterol synthesis markers 3. However, these are primarily research tools and not standard clinical practice.

Lipoprotein(a)

Lipoprotein(a) measurement helps explain FH-like phenotypes in patients without monogenic causes and aids in risk stratification 2. Elevated Lp(a) can contribute to phenotypic severity.

Polygenic Risk Score

Polygenic risk scores (PRS) based on single-nucleotide polymorphisms are emerging tools 2, 4:

  • Help identify polygenic severe hypercholesterolemia when monogenic variants are absent
  • Act as phenotype modifiers in confirmed FH cases
  • Not yet ready for routine clinical implementation but show promise 4

Practical Algorithm for Laboratory Workup

  1. Initial screening: Measure LDL-C (fasting preferred)
  2. Confirm elevation: Repeat LDL-C measurement 2-12 weeks later
  3. Complete lipid panel: Total cholesterol, HDL-C, triglycerides, non-HDL-C, ApoB
  4. Exclude secondary causes: TSH, glucose, liver function, renal function, urinalysis
  5. Genetic testing: Order panel for LDLR, APOB, PCSK9, LDLRAP1 (and APOE if available)
  6. Consider Lp(a): Especially if genetic testing is negative but phenotype suggests FH
  7. Family cascade screening: Once index case confirmed, test first-degree relatives

Common Pitfalls to Avoid

  • Don't rely on single LDL-C measurement - always confirm with repeat testing 1
  • Don't use adult diagnostic criteria (like Dutch Lipid Clinic Network) in children - they are inappropriate for pediatric populations 1
  • Don't dismiss FH diagnosis if genetic testing is negative - clinical diagnosis remains valid 1
  • Don't forget to adjust for medications when interpreting LDL-C in treated patients 1
  • Don't use Friedewald equation with high triglycerides - it becomes unreliable 1

References

2
Research

Update on genetics of familial hypercholesterolemia.

Current opinion in lipidology, 2026

Related Questions

When should an adult with LDL‑C ≥190 mg/dL, premature atherosclerotic cardiovascular disease, or a first‑degree relative with early coronary disease or familial hypercholesterolemia undergo a comprehensive genetic lipid panel, and which genes should be sequenced?
What is the effect of beet juice on LDL‑cholesterol levels in a patient with familial hypercholesterolemia?
How can I determine if I have familial hyperlipidemia?
What are the clinical signs of hypercholesterolemia in children?
What is the clinical significance of apolipoprotein A (apoA) levels in a patient with homozygous familial hypercholesterolemia?
How should I manage a patient with mild depression, predominant anxiety, and low energy who is currently taking sertraline, and is bupropion appropriate given its potential to increase anxiety?
Will switching the timing of valproic acid (Depakote) to bedtime reduce daytime sleepiness and improve nighttime sleep?
What intravenous antibiotics are recommended for a 63-year-old male with suspected osteomyelitis of the right great toe, deep plantar ulcer, severe toe swelling, foul gangrenous odor, and no known diabetes?
What is the recommended clarithromycin dose for children?
What is the recommended Claritin (loratadine) dose for pediatric patients, specifically for children aged 2 to 5 years and for those 6 years and older?
In a healthy male with a family history of obstructive sleep apnea and dementia, should very mild obstructive sleep apnea without hypoxic burden be treated now or can treatment be deferred until it becomes more severe?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.